MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance.

The UAB Molecular Genetic Pathology Fellowship Program is participating in the Molecular Genetic Pathology Unified Timeline for the 2025-2026 fellowship year. For ...

A historic new study reveals how OpenAI’s o3 model helped Boston Children’s Hospital diagnose patients with rare genetic ...

SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test ...

Type to search articles, cases, and authors. Press ↵ to view all results. Granted, vacated, and remanded in light of <em><a href=https://www.scotusblog.com/case ...

Cancer genetic counseling and testing have become integral to medicine given expanding knowledge of genetic risk and recognition that a substantial fraction of cancer is hereditary. Access to genetic ...

BOSTON--(BUSINESS WIRE)--Invicro LLC, and Ambry Genetics, both Konica Minolta precision medicine companies and leading providers of quantitative biomarker and genomic profiling services, today ...

Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...

VICTORY! On June 13, 2013, the U.S. Supreme Court invalidated patents on two genes associated with hereditary breast and ovarian cancer in response to a lawsuit filed by the American Civil Liberties ...